FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108257295> ?p ?o ?g. }

• W2108257295 endingPage "1704" @default.
• W2108257295 startingPage "1699" @default.
• W2108257295 abstract "Positron emission tomographic (PET) scanning utilizing [18F]fluorodeoxyglucose (FDG) is a new method of tumor imaging based on the increased glucose metabolic activity of malignant tumors. In Hodgkin's disease (HD), PET has proven value for the evaluation of residual masses following treatment and for the early diagnosis of relapse. In the initial staging of HD, PET frequently shows a higher stage than conventional methods (upstaging by PET). In the present study, we evaluated the frequency of stage changes by PET in a multicenter setting and determined its prognostic relevance.A total of 73 patients with newly diagnosed HD were staged with both conventional methods and whole-body PET scanning. All histological types and stages were represented. The median time of follow-up after the initial diagnosis was 25 months (range 1 month to 5 years). The response to treatment was determined by standard clinical and diagnostic criteria. For the purpose of this analysis, data from a PET center associated with a university medical center and a PET center associated with a group oncology practice were combined.A total of 21 patients (28.8%) were upstaged by PET compared with conventional methods. In two cases (2.7%), a lower stage was suggested by PET scanning. With one possible exception, the upstaging had no obvious clinical or biological correlate. Among 12 patients in stage I (A + B) by conventional methods, seven were upstaged by PET (58.3%), four to stage II, one to stage III and two to stage IV. Among 42 patients in stage II, eight were upstaged by PET (19.0%), six to stage III and two to stage IV. Among 12 patients in stage III, six (50%) were upstaged to stage IV by PET. If only early-stage patients and major changes are considered (stages IA-IIB to III or IV), among 49, 10 were upstaged to III or IV, whereas in 39 staging was unchanged following PET. In the former group, three relapsed or were refractory compared with none in the latter group (P<0.006). In advanced stage patients (IIIA or IIIB) a trend toward treatment failure was apparent in patients who were upstaged by PET.PET scanning is an interesting new modality for the accurate staging of patients with HD and frequently shows a higher stage than conventional methods. PET should be performed at initial diagnosis and should be included in prospective studies of patients with HD. Upstaging by PET may represent a risk factor for a more advanced stage or a biologically more aggressive tumor. Patients with early-stage disease as identified by conventional methods have a significant risk of treatment failure if a more advanced stage is indicated by PET. At present, major stage changes suggested by PET imaging should be confirmed by an independent diagnostic method." @default.
• W2108257295 created "2016-06-24" @default.
• W2108257295 creator A5005459489 @default.
• W2108257295 creator A5040260495 @default.
• W2108257295 creator A5044583245 @default.
• W2108257295 creator A5047502353 @default.
• W2108257295 creator A5053295195 @default.
• W2108257295 creator A5054469948 @default.
• W2108257295 creator A5062197967 @default.
• W2108257295 creator A5085639265 @default.
• W2108257295 date "2004-11-01" @default.
• W2108257295 modified "2023-10-16" @default.
• W2108257295 title "Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease" @default.
• W2108257295 cites W1973619753 @default.
• W2108257295 cites W1990524729 @default.
• W2108257295 cites W2004683676 @default.
• W2108257295 cites W2028927629 @default.
• W2108257295 cites W2034526812 @default.
• W2108257295 cites W2045282508 @default.
• W2108257295 cites W204862473 @default.
• W2108257295 cites W2049066037 @default.
• W2108257295 cites W2071376396 @default.
• W2108257295 cites W2089909642 @default.
• W2108257295 cites W2100007574 @default.
• W2108257295 cites W2107659368 @default.
• W2108257295 cites W2110807913 @default.
• W2108257295 cites W2112108745 @default.
• W2108257295 cites W2112269002 @default.
• W2108257295 cites W2121894144 @default.
• W2108257295 cites W2149602343 @default.
• W2108257295 cites W2161762488 @default.
• W2108257295 cites W2260527364 @default.
• W2108257295 cites W2317418958 @default.
• W2108257295 cites W2425470053 @default.
• W2108257295 cites W2464962743 @default.
• W2108257295 cites W2587033975 @default.
• W2108257295 cites W4211188662 @default.
• W2108257295 doi "https://doi.org/10.1093/annonc/mdh426" @default.
• W2108257295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15520074" @default.
• W2108257295 hasPublicationYear "2004" @default.
• W2108257295 type Work @default.
• W2108257295 sameAs 2108257295 @default.
• W2108257295 citedByCount "94" @default.
• W2108257295 countsByYear W21082572952012 @default.
• W2108257295 countsByYear W21082572952013 @default.
• W2108257295 countsByYear W21082572952014 @default.
• W2108257295 countsByYear W21082572952015 @default.
• W2108257295 countsByYear W21082572952016 @default.
• W2108257295 countsByYear W21082572952017 @default.
• W2108257295 countsByYear W21082572952018 @default.
• W2108257295 countsByYear W21082572952019 @default.
• W2108257295 countsByYear W21082572952020 @default.
• W2108257295 countsByYear W21082572952021 @default.
• W2108257295 countsByYear W21082572952022 @default.
• W2108257295 countsByYear W21082572952023 @default.
• W2108257295 crossrefType "journal-article" @default.
• W2108257295 hasAuthorship W2108257295A5005459489 @default.
• W2108257295 hasAuthorship W2108257295A5040260495 @default.
• W2108257295 hasAuthorship W2108257295A5044583245 @default.
• W2108257295 hasAuthorship W2108257295A5047502353 @default.
• W2108257295 hasAuthorship W2108257295A5053295195 @default.
• W2108257295 hasAuthorship W2108257295A5054469948 @default.
• W2108257295 hasAuthorship W2108257295A5062197967 @default.
• W2108257295 hasAuthorship W2108257295A5085639265 @default.
• W2108257295 hasBestOaLocation W21082572951 @default.
• W2108257295 hasConcept C126322002 @default.
• W2108257295 hasConcept C126838900 @default.
• W2108257295 hasConcept C127077266 @default.
• W2108257295 hasConcept C146357865 @default.
• W2108257295 hasConcept C151730666 @default.
• W2108257295 hasConcept C199374082 @default.
• W2108257295 hasConcept C2775842073 @default.
• W2108257295 hasConcept C2777415128 @default.
• W2108257295 hasConcept C2780073493 @default.
• W2108257295 hasConcept C2989005 @default.
• W2108257295 hasConcept C3017724952 @default.
• W2108257295 hasConcept C71924100 @default.
• W2108257295 hasConcept C86803240 @default.
• W2108257295 hasConceptScore W2108257295C126322002 @default.
• W2108257295 hasConceptScore W2108257295C126838900 @default.
• W2108257295 hasConceptScore W2108257295C127077266 @default.
• W2108257295 hasConceptScore W2108257295C146357865 @default.
• W2108257295 hasConceptScore W2108257295C151730666 @default.
• W2108257295 hasConceptScore W2108257295C199374082 @default.
• W2108257295 hasConceptScore W2108257295C2775842073 @default.
• W2108257295 hasConceptScore W2108257295C2777415128 @default.
• W2108257295 hasConceptScore W2108257295C2780073493 @default.
• W2108257295 hasConceptScore W2108257295C2989005 @default.
• W2108257295 hasConceptScore W2108257295C3017724952 @default.
• W2108257295 hasConceptScore W2108257295C71924100 @default.
• W2108257295 hasConceptScore W2108257295C86803240 @default.
• W2108257295 hasIssue "11" @default.
• W2108257295 hasLocation W21082572951 @default.
• W2108257295 hasLocation W21082572952 @default.
• W2108257295 hasOpenAccess W2108257295 @default.
• W2108257295 hasPrimaryLocation W21082572951 @default.
• W2108257295 hasRelatedWork W2012279166 @default.
• W2108257295 hasRelatedWork W2021166906 @default.

• next